{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.6","upperLimit":"56.4","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"}],"units":"Participants"}],"description":"Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, will be estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Down Syndrome HR patients receive post-Induction therapy regimen","id":"OG000","title":"DS HR B-ALL"}],"paramType":"NUMBER","populationDescription":"DS patients received MBFM-interim maintenance intermediate dose methotrexate (includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"Up to 10 years","title":"Toxicity and Tolerability of MBFM-interim Maintenance Intermediate Dose Methotrexate (IMIDM) in Children With Down Syndrome","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}